Zhejiang Wolwo Bio-Pharmaceutical (300357) Fundamentals 2026 — P/E 29.9x, Revenue Analysis | SniperIQ
Zhejiang Wolwo Bio-Pharmaceutical (300357) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥12.8B, trading at ¥24.48 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Wolwo Bio-Pharmaceutical's valuation (P/E 29.9x, P/B 4.7x), profitability (net margin 39.2%), revenue (¥1.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Wolwo Bio-Pharmaceutical's market cap?
Zhejiang Wolwo Bio-Pharmaceutical (300357) has a market capitalization of approximately ¥12.8B, trading at ¥24.48 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Wolwo Bio-Pharmaceutical's P/E ratio?
Zhejiang Wolwo Bio-Pharmaceutical's trailing twelve-month P/E ratio is 29.9x, with a price-to-book (P/B) of 4.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Wolwo Bio-Pharmaceutical?
Zhejiang Wolwo Bio-Pharmaceutical runs a net profit margin of 39.2%, a gross margin of 95.3%, and an operating margin of 41.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Wolwo Bio-Pharmaceutical generate?
Zhejiang Wolwo Bio-Pharmaceutical reported revenue of ¥1.1B for fiscal year 2025, with net income of ¥381M and earnings per share (EPS) of 0.73. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Wolwo Bio-Pharmaceutical pay a dividend?
Zhejiang Wolwo Bio-Pharmaceutical offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Wolwo Bio-Pharmaceutical financially healthy?
Zhejiang Wolwo Bio-Pharmaceutical carries a debt-to-equity ratio of 0.01x and a current ratio of 26.14x, with a market beta of 0.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Wolwo Bio-Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Wolwo Bio-Pharmaceutical (300357) the key facts are: market cap ¥12.8B, P/E 29.9x, revenue ¥1.1B, 52-week range 20.57-35.84. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Wolwo Bio-Pharmaceutical's full fundamentals live
Get Zhejiang Wolwo Bio-Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.